Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of October 2025. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions.
| Transaction Date | Executive Name | Position | Transaction Type | Volume | Price (GBP) |
|---|---|---|---|---|---|
| 2025-10-29 | Regis Simard | President, Global Supply Chain | Sale | 37,000 | 16.8395 |
| 2025-10-29 | Deborah Waterhouse | CEO, ViiV Healthcare and President, Global Health | Sale | 120,000 | 16.8865 |
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It reports two distinct sales of Ordinary Shares (ISIN: GB00BN7SWP63) executed on the London Stock Exchange (XLON) on October 29, 2025.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of executive share sales.
Key Facts for Investor Verification
- Two senior executives sold a combined total of 157,000 ordinary shares on October 29, 2025.
- The sales were executed at prices ranging between £16.8395 and £16.8865 per share.
- Regis Simard (President, Global Supply Chain) sold 37,000 shares.
- Deborah Waterhouse (CEO, ViiV Healthcare) sold 120,000 shares.
- The filing does not disclose the total remaining shareholdings of these executives post-transaction.